Related Experiment Videos
The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses.
1Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Starnberg, Germany. Peter.Trenkwalder@klinikum-starnberg.de
Summary
Candesartan treatment in elderly patients showed reduced stroke risk and cardiovascular events, particularly in those without add-on therapy or with a history of stroke. Cognitive decline was also slower in patients with baseline mild cognitive impairment.
Area of Science:
- Cardiology
- Gerontology
- Neurology
Background:
- The Study on COgnition and Prognosis in the Elderly (SCOPE) initially reported on candesartan's effects in older adults.
- Blood pressure reduction was similar between candesartan and control groups in the original SCOPE trial.
Purpose of the Study:
- To investigate subgroup analyses of cardiovascular and cognitive endpoints from the SCOPE trial.
- To identify specific patient groups benefiting from candesartan-based treatment.
Main Methods:
- Post hoc analysis of cardiovascular endpoints in patients without add-on treatment.
- Analysis of baseline characteristics including age, sex, diabetes, hypertension, and stroke history.
- Cognitive endpoint analysis in patients with Mini Mental State Examination (MMSE) scores of 24-28 and those with more extensive cognitive assessments.
Main Results:
- Candesartan significantly reduced major cardiovascular events (RR 0.68) and mortality (RR 0.73) in patients without add-on treatment.
- Risk reductions for cardiovascular events and stroke were most pronounced in patients with a history of stroke.
- Patients with baseline MMSE scores of 24-28 showed significantly less cognitive decline with candesartan (difference 0.49).
Conclusions:
- Candesartan-based treatment offers cardiovascular benefits, especially for elderly patients without add-on therapy and those with prior stroke.
- The drug demonstrated a potential to slow cognitive decline in individuals with mild cognitive impairment at baseline.
- Subgroup analyses provide further insight into the efficacy of candesartan in specific elderly populations.